Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Ayala Pharmaceuticals, Inc. stock logo
ADXS
Ayala Pharmaceuticals
$0.12
$0.06
$0.00
$0.78
$5.13M1.175,773 shs6 shs
BioLineRx Ltd. stock logo
BLRX
BioLineRx
$4.63
+0.4%
$4.11
$2.30
$35.60
$19.72M1.25234,004 shs36,037 shs
Intec Pharma Ltd stock logo
NTEC
Intec Pharma
$13.52
$8.80
$36.88
$8.65M0.83543,436 shs988,300 shs
NextTrip, Inc. stock logo
NTRP
NextTrip
$3.55
-6.3%
$0.96
$0.68
$3.85
$27.17M1.5428,100 shs22,300 shs
Alterity Therapeutics Limited stock logo
PRAN
Alterity Therapeutics
$4.15
+2.6%
$1.41
$1.09
$2.91
$36.94M1.05130,956 shs11,274 shs
(Almost)  Everything You Need To Know About The EV Market Cover

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Ayala Pharmaceuticals, Inc. stock logo
ADXS
Ayala Pharmaceuticals
0.00%+343.91%+263.44%+301.00%-38.15%
BioLineRx Ltd. stock logo
BLRX
BioLineRx
0.00%+4.51%-19.34%+83.73%-78.82%
Intec Pharma Ltd stock logo
NTEC
Intec Pharma
0.00%0.00%0.00%0.00%0.00%
NextTrip, Inc. stock logo
NTRP
NextTrip
0.00%+1.14%+25.44%-33.27%+68.25%
Alterity Therapeutics Limited stock logo
PRAN
Alterity Therapeutics
0.00%+5.51%-13.74%+41.50%+127.10%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Ayala Pharmaceuticals, Inc. stock logo
ADXS
Ayala Pharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A
BioLineRx Ltd. stock logo
BLRX
BioLineRx
2.6951 of 5 stars
3.83.00.00.03.00.00.6
Intec Pharma Ltd stock logo
NTEC
Intec Pharma
N/AN/AN/AN/AN/AN/AN/AN/A
NextTrip, Inc. stock logo
NTRP
NextTrip
1.823 of 5 stars
3.03.00.00.01.10.01.3
Alterity Therapeutics Limited stock logo
PRAN
Alterity Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Ayala Pharmaceuticals, Inc. stock logo
ADXS
Ayala Pharmaceuticals
0.00
N/AN/AN/A
BioLineRx Ltd. stock logo
BLRX
BioLineRx
3.50
Strong Buy$26.00461.56% Upside
Intec Pharma Ltd stock logo
NTEC
Intec Pharma
0.00
N/AN/AN/A
NextTrip, Inc. stock logo
NTRP
NextTrip
2.00
Hold$5.0040.85% Upside
Alterity Therapeutics Limited stock logo
PRAN
Alterity Therapeutics
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest PRAN, BLRX, NTEC, NTRP, and ADXS Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/17/2025
BioLineRx Ltd. stock logo
BLRX
BioLineRx
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy
5/30/2025
BioLineRx Ltd. stock logo
BLRX
BioLineRx
Jones Trading
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold ➝ Strong-Buy
5/28/2025
BioLineRx Ltd. stock logo
BLRX
BioLineRx
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy
(Data available from 7/7/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Ayala Pharmaceuticals, Inc. stock logo
ADXS
Ayala Pharmaceuticals
$3.24M1.58N/AN/A($2.06) per share-0.06
BioLineRx Ltd. stock logo
BLRX
BioLineRx
$28.94M0.68N/AN/A$4.04 per share1.15
Intec Pharma Ltd stock logo
NTEC
Intec Pharma
N/AN/AN/AN/A$16.18 per shareN/A
NextTrip, Inc. stock logo
NTRP
NextTrip
$500K54.32N/AN/A$4.16 per share0.85
Alterity Therapeutics Limited stock logo
PRAN
Alterity Therapeutics
$150K246.23N/AN/A$1.40 per share2.96
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Ayala Pharmaceuticals, Inc. stock logo
ADXS
Ayala Pharmaceuticals
-$48.07M-$7.98N/AN/AN/AN/AN/AN/A
BioLineRx Ltd. stock logo
BLRX
BioLineRx
-$9.22M-$8.80N/AN/AN/A-15.21%-23.93%-6.80%8/21/2025 (Estimated)
Intec Pharma Ltd stock logo
NTEC
Intec Pharma
-$14.13M-$16.32N/AN/AN/AN/A-96.37%-68.87%N/A
NextTrip, Inc. stock logo
NTRP
NextTrip
-$10.12MN/A0.0029.58N/A-2,015.64%-580.52%-165.33%N/A
Alterity Therapeutics Limited stock logo
PRAN
Alterity Therapeutics
-$6.40M-$0.70N/AN/AN/AN/AN/AN/A

Latest PRAN, BLRX, NTEC, NTRP, and ADXS Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/27/2025Q1 2025
BioLineRx Ltd. stock logo
BLRX
BioLineRx
-$0.84$1.39+$2.23$1.39$7.72 million$11.75 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Ayala Pharmaceuticals, Inc. stock logo
ADXS
Ayala Pharmaceuticals
N/AN/AN/AN/AN/A
BioLineRx Ltd. stock logo
BLRX
BioLineRx
N/AN/AN/AN/AN/A
Intec Pharma Ltd stock logo
NTEC
Intec Pharma
N/AN/AN/AN/AN/A
NextTrip, Inc. stock logo
NTRP
NextTrip
N/AN/AN/AN/AN/A
Alterity Therapeutics Limited stock logo
PRAN
Alterity Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Ayala Pharmaceuticals, Inc. stock logo
ADXS
Ayala Pharmaceuticals
N/AN/AN/A
BioLineRx Ltd. stock logo
BLRX
BioLineRx
0.37
2.27
2.04
Intec Pharma Ltd stock logo
NTEC
Intec Pharma
N/A
2.34
2.34
NextTrip, Inc. stock logo
NTRP
NextTrip
N/A
0.96
0.96
Alterity Therapeutics Limited stock logo
PRAN
Alterity Therapeutics
N/A
4.37
N/A

Institutional Ownership

CompanyInstitutional Ownership
Ayala Pharmaceuticals, Inc. stock logo
ADXS
Ayala Pharmaceuticals
7.18%
BioLineRx Ltd. stock logo
BLRX
BioLineRx
1.56%
Intec Pharma Ltd stock logo
NTEC
Intec Pharma
22.37%
NextTrip, Inc. stock logo
NTRP
NextTrip
3.81%
Alterity Therapeutics Limited stock logo
PRAN
Alterity Therapeutics
3.63%

Insider Ownership

CompanyInsider Ownership
Ayala Pharmaceuticals, Inc. stock logo
ADXS
Ayala Pharmaceuticals
0.63%
BioLineRx Ltd. stock logo
BLRX
BioLineRx
1.10%
Intec Pharma Ltd stock logo
NTEC
Intec Pharma
3.30%
NextTrip, Inc. stock logo
NTRP
NextTrip
9.60%
Alterity Therapeutics Limited stock logo
PRAN
Alterity Therapeutics
38.80%
CompanyEmployeesShares OutstandingFree FloatOptionable
Ayala Pharmaceuticals, Inc. stock logo
ADXS
Ayala Pharmaceuticals
2042.63 million42.36 millionNot Optionable
BioLineRx Ltd. stock logo
BLRX
BioLineRx
404.26 million4.22 millionOptionable
Intec Pharma Ltd stock logo
NTEC
Intec Pharma
40898,000N/AOptionable
NextTrip, Inc. stock logo
NTRP
NextTrip
57.65 million6.92 millionNo Data
Alterity Therapeutics Limited stock logo
PRAN
Alterity Therapeutics
148.90 millionN/ANot Optionable

Recent News About These Companies

ATHE Alterity Therapeutics Limited - Seeking Alpha
Alterity Therapeutics Reveals Top Option Holders
Alterity Therapeutics completes placement
Alterity Therapeutics announces regulatory notice
Alterity Therapeutics Ltd PBN
Alterity Therapeutics to List New Securities on ASX
Alterity Therapeutics raises A$40M in placement

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Ayala Pharmaceuticals stock logo

Ayala Pharmaceuticals NASDAQ:ADXS

$0.12 0.00 (0.00%)
As of 07/3/2025

Ayala Pharmaceuticals, Inc., a clinical-stage oncology company, primarily focuses on developing and commercializing small molecule therapeutics for people living with rare tumors and aggressive cancers. The company's lead candidates under development include AL102, an oral gamma secretase inhibitor for desmoid tumors; and aspacytarabine (BST-236), a novel proprietary anti-metabolite for first line treatment in unfit acute myeloid leukemia. Ayala Pharmaceuticals, Inc. is based in Wilmington, Delaware.

BioLineRx stock logo

BioLineRx NASDAQ:BLRX

$4.63 +0.02 (+0.43%)
Closing price 07/3/2025 02:55 PM Eastern
Extended Trading
$4.60 -0.04 (-0.76%)
As of 08:35 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma. It also develops BL-5010, a pen-like applicator containing an acidic aqueous solution for the non-surgical removal of skin lesions. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel.

Intec Pharma stock logo

Intec Pharma NASDAQ:NTEC

Intec Pharma Ltd. is a clinical-stage biopharmaceutical company, which engages in the development of drugs based on proprietary Accordion Pill platform technology. Its Accordion Pill technology is an oral drug delivery system that is designed to improve the efficacy and safety of existing drugs and drugs under development by utilizing an efficient gastric retention and specific release mechanism. The company was founded by Zvika Joseph on October 23, 2000 and is headquartered in Jerusalem, Israel.

NextTrip stock logo

NextTrip NASDAQ:NTRP

Neurotrope, Inc., a biopharmaceutical company, focuses on the development of a product platform for the treatment of Alzheimer's disease. The company's lead product candidate is bryostatin, a natural product isolated from a marine invertebrate organism, a bryozoan called Bugula neritina. It also develops bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as Fragile X syndrome, multiple sclerosis, and niemann-pick type C diseases. The company has a license agreement with The Board of Trustees of the Leland Stanford Junior University for the use of bryostatin structural derivatives, known as bryologs, for use in the treatment of central nervous system disorders, lysosomal storage diseases, stroke, cardio protection, and traumatic brain injury; and a license agreement to an accelerated synthesis of bryostatin-1. Neurotrope, Inc. also has a cooperative research and development agreement with the National Cancer Institute for the research and clinical development of Bryostatin-1. The company was founded in 2012 and is based in New York, New York.

Alterity Therapeutics stock logo

Alterity Therapeutics NASDAQ:PRAN

Alterity Therapeutics Ltd. engages in the development of therapeutic drugs designed to treat the underlying causes of degeneration of the brain as the aging process progresses. It focuses on Parkinson's movement disorders, Alzheimer's disease, Huntington disease, and other neurodegenerative disorders. The company was founded by Geoffrey Paul Kempler on November 11, 1997 and is headquartered in Melbourne, Australia.